Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Pre-commercialization of circadian clock-drug interactions screening tool for therapeutic applications

Descrizione del progetto

Screening innovativo per la modulazione dell’efficacia dei farmaci da parte degli orologi circadiani

Gli orologi circadiani interni stabiliscono i tempi dei ritmi circadiani, regolando vari processi del corpo umano quali i cicli sonno/veglia, l’attività ormonale, il ritmo della temperatura, l’alimentazione e la digestione. L’alterazione degli orologi circadiani è associata a un ampio spettro di malattie, dai disturbi del sonno al cancro. I bersagli terapeutici dei farmaci potrebbero essere influenzati dagli orologi circadiani e i tempi di somministrazione dei farmaci possono massimizzarne l’efficacia. Il progetto CircaSCOPE, finanziato dall’UE, propone una metodologia innovativa ad alto rendimento per la costruzione di curve di transizione di fase ad alta risoluzione per lo screening di farmaci che modulano l’orologio. La metodologia sviluppata migliorerà la scoperta di farmaci, mirando alle malattie associate all’alterazione circadiana e identificando i farmaci con effetti collaterali che influenzano gli orologi.

Obiettivo

Circadian clocks carry an immense importance to human health, as clock disruption is related to various malignancies from sleep disorders through diabetes to cancer. Furthermore, many drug targets are influenced by circadian clocks. In order to maximize drugs efficacy while minimizing side effects, it is necessary to consider the drugs time-of-administration, also known as chronotherapy. These revelations are critical for drug administration and development. However, their practical implementation is tempered by the lack of suitable research tools that bridge the gap from the bench to the clinic.
The time-dependent effect of an intervention on the clock is represented by the Phase Transition Curve (PTC). PTCs retrieval is laborious and challenging, consequently they were mostly overlooked in the pharmaceutical R&D process. In the ERC Project CIRCOMMUNICATION, we studied clock-resetting mechanisms, which led to the development of CircaSCOPE, an efficient high-throughput methodology for high-resolution PTC construction.
CircaSCOPE can be used as a powerful screening method for clock-modulating drugs, either for the purpose of targeting pathologies associated with circadian disruption, or to identify drugs which elicit unwanted side-effects on the clock. Once fully developed and systematically integrated in chrono-medicine, CircaSCOPE has the potential to improve drug discovery and yield medicines with better therapeutic index.
Here, we detail our plan for the first steps toward commercializing of our innovation. We will demonstrate the applicability of this approach through drug libraries screens and expand the repertoire of cell types that the system relies on. In addition, we will explore different commercialization strategies and interact with potential stakeholders and end-users. Given the medical importance of circadian effects, wed envisage that CircaSCOPE will become as a gold-standard procedure in future drugs development.

Campo scientifico (EuroSciVoc)

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) ERC-2022-POC1

Vedi tutti i progetti finanziati nell’ambito del bando

Istituzione ospitante

WEIZMANN INSTITUTE OF SCIENCE
Contributo netto dell'UE
€ 150 000,00
Costo totale
Nessun dato

Beneficiari (1)